Biopharma Supply Chain and Operational Scale Advisory
Biopharma supply chain disruptions cost the global pharmaceutical industry an estimated USD 35 billion annually - and the risk profile is increasing, not decreasing. A 2025 Deloitte survey found that 73% of biopharma executives cited supply chain resilience as a top-three strategic priority. Yet, fewer than 30% had completed a formal supply chain risk assessment in the previous 24 months. The FDA issued 483 observations related to supply chain and manufacturing quality to 67 biopharma companies in 2025 - each one a potential deal-killer in an M&A diligence process and a potential regulatory action that can delay or derail a commercial launch.
The CDMO market - the manufacturing backbone of the biopharma industry - reached USD 220 billion in 2025 and is projected to grow to USD 390 billion by 2030 at a CAGR of 12.1%. Selecting the right CDMO partner, negotiating contracts that protect your interests throughout the full development and commercialization lifecycle, and building quality systems that withstand both FDA inspections and acquisition due diligence are decisions that compound over time. Getting them wrong is expensive. Getting them right is a competitive advantage.
Katogen helps biopharma companies build the supply chain and operational infrastructure needed to support growth - drawing on 35+ years of hands-on experience building, scaling, and turning around biopharma operations across multiple geographies, including North America, Europe, and Asia. Every supply chain strategy Katogen delivers is stress-tested against realistic growth scenarios - not optimistic assumptions.
What We Do
Supply Chain Strategy and Design
We help companies build supply chain strategies that are scalable, resilient, and aligned with their commercial and regulatory requirements — from raw material sourcing through finished product distribution.
Operational Scalability Planning
Can your supply chain handle 3x volume? 10x? We help companies stress-test their operational infrastructure against realistic growth scenarios — and build the roadmap to close the gaps before they become constraints.
CDMO Selection and Partnership Management
Selecting the right contract development and manufacturing organization is one of the most consequential decisions a biopharma company makes. We help companies develop CDMO selection criteria, run rigorous selection processes, and negotiate contracts that protect their interests across the full development and commercialization lifecycle.
Quality Systems and Regulatory Readiness
A quality system that cannot withstand FDA inspection is a liability, not an asset. We help companies build quality management systems that are both operationally effective and inspection-ready — and that will survive the scrutiny of a sophisticated acquirer's diligence team.
Supply Chain Risk Management
Single-source dependencies, geopolitical risk, API supply concentration — we help companies identify and mitigate the supply chain risks that are most likely to disrupt their business and most likely to be flagged in diligence.
Built for the Operator's Seat
Who This Is For?
CEOs and COOs at growth-stage and mid-sized biopharma companies building or scaling their operational infrastructure — particularly those preparing for a launch, a significant volume increase, a regulatory inspection, or a potential transaction.
Why Katogen?
We have built and scaled biopharma supply chains across multiple companies, modalities, and geographies. We understand the operational decisions that create long-term competitive advantage — and the ones that create long-term risk.
WORK WITH KATOGEN
If you are navigating a strategic inflection point — a capital raise, an acquisition, a turnaround, a regulatory challenge, or simply a moment where you need an experienced operator in your corner — we would welcome the conversation. Engagements are selective. The first step is a direct conversation to understand your situation and determine where Katogen can add the most value.
